Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - ALS
 More »

  • Denovo Partners with ALS Nonprofit to ID Biomarkers
    The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers are partnering in a pharmacogenomics-based effort to identify potential responder groups for drugs being studied in ...
    5-10-2013
  • Stem Cell Screen Reveals Promising Target for ALS
    killed in amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) than two drugs that ... discovery to ALS. The disease is associated with the progressive death of motor neurons. ...
    4-19-2013
  • BMS, Vertex Plan Phase II Studies of Hep C Combo Therapy
    ... Vertex gained worldwide rights to VX-135, which until Phase II studies was named ALS-2200, through an exclusive licensing agreement signed with Alios BioPharma, in June 2011. The ...
    4-5-2013
  • Medicine: Getting Personal
    ... of fetal-derived neural stems cells in patients with amyotrophic lateral sclerosis (ALS), for example. 6. Smith and Nephew announces acquisition of bioactive woundcare company ...
    3-15-2013
  • Can Fat Fight Brain Cancer?
    ... MSCs, whether derived from bone marrow or fat, have been studied in animal models to treat trauma, Parkinson's disease, ALS, and other diseases. Results of this Johns Hopkins ...
    3-12-2013
  • Addressing Unmet Medical Needs with Complex Carbohydrate Chemistry
    ... It is involved in many pathological conditions such as heart attack, brain injuries and stroke, neurodegenerative diseases such as Alzheimer's dementia, Lou Gehrig's disease (ALS), ...
    2-28-2013
  • Biogen Idec ALS Drug Strikes Out
    sclerosis (ALS or Lou Gehrig's disease), after the drug candidate failed a pivotal Phase III clinical trial-though the company insisted that it remains committed to ALS research. ...
    1-4-2013
  • The New Economics of Orphan Diseases
    ... 2002 and 2010. For myasthenia gravis, the growth rate is expected to be 6.3% between 2010 and 2017, up from 3.9% between 2002 and 2010. ALS therapeutics, however, will slow. ...
    1-1-2013
  • ALS Research Consortium Spearheaded by Biogen Idec
    (ALS). Participants hope that coordinating research and sharing results across various disciplines will greatly accelerate the understanding of the mechanism of ALS and the ...
    12-20-2012
  • ALS TDI Adds Another Partner
    The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes formed a research collaboration to speed the discovery of potential treatments for ALS. About 30,000 ...
    12-4-2012
  • In Vitro Clinical Trials: Not that Far-Fetched
    ... Stroke (NINDS) funded three consortia to develop iPS cell lines from individuals with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). ...
    10-31-2012
  • MJFF Supports Trial Evaluating Treatment for Levodopa-Induced...
    brain injury, Parkinson's disease, multiple sclerosis, or ALS. Avanir's other marketed drug, Abreva (docosanol) is approved for the treatment of orofacial herpes simplex (HSV1). ...
    10-23-2012
  • Protecting Neurons in Parkinson's Disease and ALS
    in animal models of both Parkinson's disease and amyotrophic lateral sclerosis (ALS). ... drugs against both Parkinson's disease and ALS. Their studies showed that P7C3 A20 and, to ...
    10-2-2012
  • Stem Cells Help Rats Recover Lower-Body Movement
    used in a recently completed Phase I clinical trial for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Neuralstem's NSI-566 spinal cord stem cells yields improved ...
    9-13-2012
  • Big Data Requires Big Solutions
    ... Dr. Reinholdt's group has used high-throughput sequencing to improve mouse models of ALS, Down syndrome, and Alzheimer's disease. Performing alignment on the laboratory's 32-core ...
    9-1-2012
  • More »

    Journal Articles

  • A Model of Motor Neuron Loss: Selective Deficits after Ricin...
    Margaret Coutts, Ling X. Kong, Hans S. Keirstead
    Journal of Neurotrauma
    motor system models lower limb paralysis and the deficits that occur in diseases like amyotrophic lateral sclerosis (ALS) and infantile progressive spinal muscular atrophy (SMA). ...
  • Individual Quality of Life is not Correlated with Health-Related...
    Christian Neudert, Maria Wasner, Gian Domenico Borasio
    Journal of Palliative Medicine
    status in palliative care patients with amyotrophic lateral sclerosis (ALS). Forty-two patients with ALS performed the following assessments: the ALS functional rating scale ...
  • Withdrawal of Invasive Home Mechanical Ventilation in Patients...
    Pia Sander Dreyer, Michael Felding, Charlotte Sønderskov Klitnæs, Charlotte Kirkegård Lorenzen
    Journal of Palliative Medicine
    in amyotrophic lateral sclerosis (ALS), physicians are increasingly confronted ... IHMV in patients with advanced stage ALS. Methods: A retrospective, descriptive ...
  • Neurologic Disease at the End of Life: Caregiver Descriptions...
    Elizabeth Ruth Goy, Julie Carter, Linda Ganzini
    Journal of Palliative Medicine
    ABSTRACT Objective: Amyotrophic lateral sclerosis (ALS) is well recognized as a terminal ... (PDRD), we compared them to patients with ALS. Methods: Family caregivers of decedent ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll